Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Delayed Quote. Delayed  - 07/28 05:38:12 pm
76.29 EUR   -0.53%
07/28 SANOFI : Merial to merge with Boehringer Ingelheim
07/28 SANOFI : Canada’s Next Generation of Bioscientists
07/28DJSANOFI : US FDA Approves Sanofi's Adlyxin to Help Treat Type 2 Diabe..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 01:58pm CEST

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.

MAIN FACTS:

- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at mimosa.spencer@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
07/28 SANOFI : Merial to merge with Boehringer Ingelheim
07/28 SANOFI : Recent Findings from Sanofi Provides New Insights into Solid Cancer (Ph..
07/28 SANOFI : Canada’s Next Generation of Bioscientists
07/28DJSANOFI : US FDA Approves Sanofi's Adlyxin to Help Treat Type 2 Diabetes
07/28 SANOFI : ​Sanofi Receives FDA Approval of AdlyxinTM for Treatment of Adult..
07/28 SANOFI : Receives FDA Approval of AdlyxinTM for Treatment of Adults with Type 2 ..
07/27DJRenault Board Cuts CEO's 2016 Pay After Spat With Shareholders
07/27DJSANOFI : 2Q 2016 -- Forecast
07/26 SANOFI : India ends in green; SC refuses early hearing
07/26 Exclusive - Teva, Mylan eye Pfizer's Brazil venture, sources say
More news
Sector news : Pharmaceuticals - NEC
07/28DJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
07/28DJALEXION PHARMACEUTICALS : Cuts Profit Guidance
07/28DJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs
07/28DJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/28 Roche's hemophilia candidate emicizumab shows encouraging results in early-st..
07/28 FDA OKs Sanofi's lixisenatide for type 2 diabetes
07/27 MANNKIND : Beware Of Dog
07/27 MY EARNINGS GAME PLAN : July 28-29
07/25 Is Biotech Finally Ready To Move Higher?
Advertisement
Financials (€)
Sales 2016 37 154 M
EBIT 2016 9 370 M
Net income 2016 5 093 M
Debt 2016 5 594 M
Yield 2016 3,91%
P/E ratio 2016 17,79
P/E ratio 2017 16,17
EV / Sales 2016 2,81x
EV / Sales 2017 2,76x
Capitalization 98 859 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 85,0 €
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-2.42%109 416
JOHNSON & JOHNSON21.47%343 198
PFIZER INC.14.16%223 490
ROCHE HOLDING LTD.-9.99%216 972
NOVARTIS AG-5.30%216 918
MERCK & CO., INC.10.94%162 206
More Results